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Abstract
Background: Gastric cancer is an aggressive disease with a poor 5-year survival and large global burden of disease.
The disease is biologically and genetically heterogeneous with a poorly understood carcinogenesis at the molecular
level. Despite the many prognostic, predictive, and therapeutic biomarkers investigated to date, gastric cancer
continues to be detected at an advanced stage with resultant poor clinical outcomes.
Main body: This is a global review of gastric biomarkers with an emphasis on HER2, E-cadherin, fibroblast growth
factor receptor, mammalian target of rapamycin, and hepatocyte growth factor receptor as well as sections on
microRNAs, long noncoding RNAs, matrix metalloproteinases, PD-L1, TP53, and microsatellite instability.
Conclusion: A deeper understanding of the pathogenesis and biological features of gastric cancer, including the
identification and characterization of diagnostic, prognostic, predictive, and therapeutic biomarkers, hopefully will
provide improved clinical outcomes.
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Background
Gastric cancer (GC) has been globally the fourth most
commonly diagnosed cancer and the second most lethal
malignancy [1, 2]. The data has recently been changing,
with WHO GLOBOCAN now reporting GC as the fifth
most common cancer and third leading cause of cancer
death in both sexes [3]. In 2015, an estimated 24,590
new GC cases and 10,720 GC deaths were diagnosed in
the USA [4]. As most patients present with advanced
unresectable or metastatic disease at the time of diagno-
sis, the overall clinical outcome of GC patients remains
unsatisfactory, with a 5-year survival rate of less than
30 % [4–6]. The incidence of GC remains high in Japan,
but the survival is higher, reported as 52 % [5, 6]. Clini-
copathological staging using the TNM system is the
major tool used by clinicians to predict GC patient
prognosis. However, GC patients of identical TNM stage
often exhibit varying clinical outcomes, suggesting that
there are additional factors that influence long-term
outcomes [7].
GC is a biologically heterogeneous disease that evolves
in the background of various genetic and epigenetic
alterations. Therefore, it is essential to have a more
comprehensive understanding of molecular variables
that affect GC disease pathways in order to develop ap-
propriate approaches for its diagnosis and treatment [6].
GC is assumed to originate from a sequential accumula-
tion of molecular and genetic alterations to stomach
epithelial cells [8], but the mechanism of carcinogenesis
remains complex and poorly understood [9, 10].
Additionally, a number of cellular phenomena, such as
tumour microenvironment, inflammation, oxidative
stress, and hypoxia, act in parallel with various molecu-
lar events to promote initiation, progression, and metas-
tasis of GC [11].
In the traditional Laurén classification, GC is divided
into two types: intestinal and diffuse types [12, 13]. The
intestinal-type adenocarcinomas characteristically form
glands, but with various degrees of differentiation. Intes-
tinal carcinomas are usually diagnosed in older patients,
mostly in the antrum, and are strongly attributed to
chronic H. pylori infection, with resultant atrophic gas-
tritis, and intestinal metaplasia [12, 13]. Diffuse gastric
carcinomas are poorly cohesive, composed of mostly
single, or small, nests of neoplastic cells that diffusely
infiltrate the gastric wall. This type is found most com-
monly in the gastric body and in younger patients.
Although this type is also associated with H. pylori in-
fection, the carcinogenetic sequence of the diffuse type
of GC is not well characterized [13].
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The consortium of The Cancer Genome Atlas (TCGA)
has recently reported comprehensive somatic changes in
GC and suggested four categories: (i) EBV-positive cases;
(ii) microsatellite instability (MSI)-positive cases; (iii)
genomically stable (GS) type (near-diploid type); and (iv)
chromosomal instability (CIN) type (Table 1, Fig. 1). The
EBV-positive tumours have been correlated with
PIK3CA mutations; high levels of DNA hypermethyla-
tion; and amplification of JAK2, PD-L1, and PDCD1LG2.
The MSI tumours display characteristic hypermutation
phenotype and downregulation of MLH1 gene. The GS
type has been associated with diffuse tumours, muta-
tions of RHOA and CDH1, or fusions involving RHO
family GTPase-activating proteins. The CIN tumours
have been associated with marked aneuploidy and focal
amplification of receptor tyrosine kinases, as well as mu-
tations of TP53 [14] (Fig. 2).
A deeper understanding of the pathogenesis and bio-
logical features of GC is necessary to further inform and
enhance early detection and treatment methods. The
discovery of new biomarkers and their application, in
conjunction with traditional cancer diagnosis, staging,
and prognosis, will help to improve early diagnosis and
patient care. The search for cancer biomarkers is carried
out in order to identify tumour cells at early stages and
predict treatment response, ultimately leading to a
favourable therapeutic outcome [15]. Biomarkers are
predominantly of four types, diagnostic, predictive, prog-
nostic, and therapeutic. A diagnostic biomarker is a non-
invasive marker for the detection of early disease. A
prognostic biomarker provides information on the likely
course of disease and thus yields important information
about therapy outcomes and patient survival as well as
provide suggestions for further treatment [15, 16]. In
contrast, a predictive biomarker is defined as a marker
that can be used to identify subpopulations of patients
who are most likely to respond (or not) to a targeted
therapy [17]. An ideal predictive marker should be reli-
able, readily available, and detectable by reasonably
acceptable laboratory techniques [18]. A therapeutic bio-
marker is a potential target for cancer therapy (Fig. 3).
Therapeutic targets are usually target proteins that are
identified as potential biomarkers for cancer but lack ac-
curate clinical evidences or trials to evaluate their pos-
ition within the history of cancer progression [16].
In this manuscript, a global review on the gastric
biomarker literature to date is undertaken, which is ded-
icated exclusively to the discussion of the role of bio-
markers in GC, specifically HER2; E-cadherin; fibroblast
growth factor receptor (FGFR)/human epidermal growth
factor receptor family (EGFR)/mammalian target of
rapamycin (mTOR)/hepatocyte growth factor receptor
(HGFR, MET); PD-L1 expression; TP53; MSI; and emer-
ging biomarkers including microRNAs, long noncoding
RNAs (LncRNAs), and matrix metalloproteinases
(MMPs) (Table 2). An English literature search on MED-
LINE combining the terms “gastric cancer” and “bio-
markers” retrieved 801 manuscripts between the years of
1995 and 2015. The primary manuscripts and their rele-
vant secondary references were reviewed.
HER2
HER2 (encoded by ERBB2, the v-erb-b2 avian erythro-
blastic leukaemia viral oncogene homolog 2) is one of the
four members of the human EGFR family (EGFR or
HER1, HER2, HER3, and HER4) in the receptor tyrosine
kinase (RTK) superfamily [15]. Unlike other HER family
members, HER2 does not contain a ligand-binding site
and signals through hetero-dimerization with other HER
family members, primarily EGFR [19]. HER2 is
expressed by normal and cancerous cells, whose gene
amplification results in protein overexpression, subse-
quent cell proliferation, growth, and cell survival by
triggering downstream signalling via the PI3K-AKT and
Table 1 Features of gastric cancer sub-types defined by TCGA. Based on 295 patients (182 males, 113 females) [14]
Molecular sub-type Anatomic distribution Histologic features Frequency Molecular
CIN • 43.0 % antrum
• 49.1 % fundus
• 64.9 % GEJ/cardia 50.0 % NA
• 26.1 % diffuse
• 60.2 % intestinal
• 52.6 % mixed
• 9.1 % non-specified
• 53.3 % M
• 44.2 % F
• TP53 mutation
• RTK-RAS activation
EBV • 5.3 % antrum
• 13.8 % fundus
• 7.0 % GEJ/cardia
• 7.2 % diffuse
• 7.7 % intestinal
• 15.8 % mixed
• 27.3 % not specified
• 11.5 % M





MSI • 27.2 % antrum
• 21.6 % fundus
• 8.8 % GEJ/cardia
• 37.5 % NA
• 8.7 % diffuse
• 24.5 % intestinal
• 15.8 % mixed
• 63.6 % not specified
• 15.4 % M




GS • 24.6 % antrum
• 15.5 % fundus
• 19.3 % GEJ/cardia 12.5 % NA
• 58.0 % diffuse
• 7.7 % intestinal
• 15.8 % mixed
• 19.8 % M
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the MAPK pathways [20, 21]. Although the prevalence,
prognostic, and predictive value of HER2 is less estab-
lished in GC compared to breast cancer, the importance
is becoming evident as studies emerge.
HER2 has become the most important biomarker in
GC. The rate of HER2 overexpression in GC has varied
in the literature, ranging from 2 % [22] to as high as
91 % [23], although most studies fall between 9 and
38 % [21, 24–27]. The rate in the Trastuzumab for
Gastric Cancer (ToGA) trial was 22.1 % [28]. Proposed
reasons for the discrepancies include:
 Choice of study specimen. Some studies have used
tissue microarray (TMA) [27, 29, 30], as opposed to
whole slide for evaluation, and/or biopsy specimens
as opposed to surgical specimens, which could be
subject to sampling error due to tumour
heterogeneity [31].
 Methodology. Different in situ hybridization (ISH)
techniques provide similar results, but interpretation
is easier with silver-enhanced ISH (SISH), which is
an advantage when diagnosing focal amplification in
very small biopsies [32–34].
 Biological. Relates to the intratumoural
heterogeneity of HER2 alterations in GC, which has
been shown to be of prognostic significance and is
the main reason for discordance between IHC and
FISH and between biopsies and resection specimens
[35–49].
 Location. The HER2 overexpression/amplification
rate is higher in tumours from the gastroesophageal
junction than in those located in more distal parts of
the stomach [40]. One study found a rate of HER2
expression in the distal stomach to be 32 % [41].
 Type. Intestinal-type adenocarcinomas are more
commonly HER2 positive than mixed or diffuse-type
neoplasms [32, 38, 42–48].
 Differentiation. HER2 amplification/overexpression
has been associated with well to moderately
differentiated tumours [22, 26, 40, 49].
 Scoring. In contrast to breast cancer, HER2
immunohistochemical expression in GC is more
Fig. 1 Molecular subtypes of gastric cancer. a Gastric cancer cases are divided into subtypes: Epstein–Barr virus (EBV)-positive (red), microsatellite
instability (MSI, blue), genomically stable (GS, green), and chromosomal instability (CIN, light purple) and ordered by mutation rate. Clinical (top)
and molecular data (top and bottom) from 227 tumours profiled with all six platforms are depicted. b A flowchart outlines how tumours were
classified into molecular subtypes. c Differences in clinical and histological characteristics among subtypes with subtypes coloured as in a, b. The
plot of patient age at initial diagnosis shows the median, 25th and 75th percentile values (horizontal bar, bottom and top bounds of the box), and
the highest and lowest values within 1.5 times the interquartile range (top and bottom whiskers, respectively). GE, gastroesophageal (reproduced
with permission from The Cancer Genome Atlas Research Network (NATURE | VOL 513 | 11 SEPTEMBER 2014 [14])
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heterogeneous (focal staining) and may exhibit
incomplete membrane staining. Therefore, an HER2
scoring system specific for GC has been developed
with separate scoring systems for endoscopic
biopsies and surgical resection specimens to ensure
standardization [33].
The role of HER2 overexpression in tumourigenesis is
not completely understood and its prognostic implica-
tion remains unclear [50]. HER2 overexpression seems
to be an early event in gastric carcinogenesis as HER2
expression rises significantly from low-grade to high-
grade dysplasia to adenocarcinoma [41]. Furthermore,
the occurrence of HER2 expression in the early stage
strongly suggests that there is no relationship between
HER2 expression and prognosis [38]. Indeed, some re-
ports show no difference in prognosis when compared
with HER2-negative tumours [22, 25–27, 30, 49, 51–54].
However, some studies do report that HER2 amplifica-
tion is associated with a poor prognosis and aggressive
disease [21, 29, 55–60]. For example, a systematic review
investigating the prognostic value of HER2 overexpres-
sion found that 20 studies (57 %) reported no difference
in overall survival (OS), 2 (6 %) showed significantly lon-
ger OS, and 13 (37 %) significantly worse OS [61]. Inter-
pretation of these controversial results is difficult due to
lack of standardization in defining HER2 overexpression
or amplification [36].
The relationships between HER2 status and other
known pathologic and prognostic characteristics are
more ambiguous. Some studies describe associations
between HER2-positive tumours and nodal disease
[30, 47], tumour size [30], depth of tumour invasion
[47], and stage [47], whereas others fail to show any
association [22, 56, 59]. Some reports have found no
correlation between HER2 positivity and TNM stage
of disease [38, 44, 46, 48]. Another study was unable
to detect significant relationships between clinicopath-
ologic factors and HER2 status with the exception
that HER2-positive tumours demonstrated a lower
prevalence of signet ring cell features [49]. One other
study noted that 100 % of tumour samples with sig-
net ring cell features were HER2 negative [22]. Since
most studies failed to adjust for other confounders, it
is difficult to interpret the reported relationship be-
tween HER2 and other histopathological variables.
HER2 expression has become the biomarker for identi-
fying patients who are likely to show a survival benefit
with trastuzumab [28]. Trastuzumab, an HER2-targeted
agent, has considerable activity in HER2-positive GC but
only benefits patients with HER2-overexpressing/ampli-
fied tumours [50]. The integration of targeted therapies
Fig. 2 Key features of gastric cancer subtypes. This schematic lists some of the salient features associated with each of the four molecular
subtypes of gastric cancer. Distribution of molecular subtypes in tumours obtained from distinct regions of the stomach is represented by inset
charts (reproduced with permission from The Cancer Genome Atlas Research Network (NATURE | VOL 513 | 11 SEPTEMBER 2014 [14])
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in GC has been slower than in some other solid tumours
[62], and trastuzumab is the only targeted agent ap-
proved for the treatment of advanced GC [50]. At the
biomolecular level, the HER2 pathway is responsible for
the repair of DNA damage (particularly, inter-strand
cross-links induced by platinum analogues), so that
HER2-targeted inhibition may synergize with chemo-
therapy and increase apoptotic stress [63]. The ToGA
phase III international study assessed the efficacy in 594
patients with HER2-positive (IHC3+ or FISH+) advanced
Fig. 3 Signalling pathway and targeted therapy in gastric cancer. Percentages signify the overall molecular characteristics in the disease: FGFR2
amplification (9 %), VEGF/VEGFR overexpression (36–40 %), EGFR amplification and overexpression (27–44 %), HER2 amplification and overexpression
(7–34 %), c-MET amplification (10–15 %), kRAS mutation (2–20 %), Raf mutation (0–3 %), PI3K mutation (4–36 %), phospho-Akt expression (29–86 %),
phospho-mTOR expression (60–88 %), PTCH1 overexpression (16%), SMO overexpression (12%), and HER3 mutations (10%, not shown). *No
clinical trials of these agents have yet been reported in gastric cancer. ‡No known numbers or percentages for these genes and pathways.
Abbreviations: EGFR epidermal growth factor receptor, FGFR fibroblast growth factor receptor, GLI glioma-associated oncogene family zinc finger 1,
HDAC histone deacetylase, HER human epidermal growth factor receptor, HGF hepatocyte growth factor, Hh Hedgehog, IGFR insulin-like growth factor
receptor, MMP matrix metalloproteinase, mTOR mammalian target of rapamycin, PDGFR platelet-derived growth factor receptor, Ptch-1 protein patched
homolog 1, Smo smoothened, VEGF vascular endothelial growth factor, VEGFR vascular endothelial growth factor receptor (reproduced with permission
from Wadhwa, R. et al. Nat. Rev. Clin. Oncol. 10, 643–655 (2013) [181])
Table 2 Frequency of co-mutations in gastric cancer [182]
Mutation HER2 CDH1 MET PIK3A P53 MSI
HER2 – 0/116 (0 %) 2/116 (1.7 %) 1/116 (0.9 %) 7/116 (6.0 %) 2/116 (1.7 %)
CDH1 – – 2/116 (1.7 %) 1/116 (0.9 %) 10/116 (8.6 %) 0/116 (0 %)
MET – – – 0/116 (0 %) 6/116 (5.2 %) 0/116 (0 %)
PIK3A – – – – 2/116 (1.7 %) 1/116 (0.9 %)
P53 – – – – – 3/116 (2.6 %)
MSI – – – – – –
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gastric or gastroesophageal junction cancer with a com-
bination of trastuzumab + conventional chemotherapy
as a treatment for GC patients. The trial demonstrated
that advanced CG patients, stratified by HER2 amplifi-
cation/overexpression, had longer median OS when
treated with trastuzumab + chemotherapy versus
chemotherapy alone (13.8 versus 11.1 months) [28].
Targeting the extracellular domain of HER2 is not the
end of the story; new ways of blocking this signalling
pathway are being pursued.
Lapatinib is a dual EGFR/HER2 reversible tyrosine
kinase inhibitor (blocking both HER1 and HER2) that
suppresses the downstream signalling involving MAPK/
Erk1/2 and PI3K/Akt pathways. The efficacy of lapati-
nib in conjunction with paclitaxel was assessed in a
randomized phase III TyTAN trial, in Asian patients
with HER2-positive advanced GC. The patients who
progressed on first-line therapy were randomized to
lapatinib in conjunction with weekly paclitaxel versus
weekly paclitaxel alone. Median OS was 11.0 months
with lapatinib plus paclitaxel versus 8.9 months with
paclitaxel alone (p = 0.10), with no significant difference
in median progression free survival (PFS) (5.4 versus
4.4 months) or time to progression (5.5 versus
4.4 months). Response rate was higher with lapatinib
plus paclitaxel versus paclitaxel alone (odds ratio, 3.85;
p < .001). However, the risk of death or disease progres-
sion was significantly lower in patients with IHC 3+ tu-
mours who were treated with lapatinib, compared with
those with IHC 0/1 or IHC 2+ tumours [64]. Ado-
trastuzumab emtansine (T-DM1) is an antibody-drug
conjugate consisting of an antimicrotubule cytotoxic
agent DM1 linked to trastuzumab. The phase II/III
Gatsby trial evaluated efficacy of ado-trastuzumab
emtansine in the second-line setting for the treatment
of HER2-positive advanced GC. A total of 412 patients
treated with first-line therapy participated in the study.
The ImmunoGen, Inc., has recently disclosed that the
trial did not meet its primary endpoint of OS. The trial
findings have not presented yet [65].
Other HER2-directed therapies such as pertuzumab
and neratinib that have demonstrated efficacy in breast
cancer have not yet been evaluated in randomized clin-
ical trials in patients with HER2-positive GC. Further-
more, dual HER2 blockade, which is an effective
strategy in breast cancer, is being investigated in a
phase II study using the combination of pertuzumab
and trastuzumab in patients with HER2-positive meta-
static GC. HER2 is a promising biomarker for targeted
treatment in GC. Several clinical trials are currently ex-
ploring HER2-directed therapy in patients with GC
using varied designs. The results of these future studies
will be helpful to know the efficacy and tolerance of
HER2-directed therapy in HER2-positive GC.
E-cadherin
CDH1, located on chromosome 16 (q 22.1), encodes the
E-cadherin transmembrane protein [66, 67]. E-cadherin
is a calcium-mediated membrane molecule that plays an
important role in adhesion and differentiation of gastric
epithelial cells, which is a very important protective
mechanism against neoplasm formation [70]. E-cadherin
is one of the most important tumour suppressor genes
in GC, and its inactivation is thought to contribute to
tumour progression via subsequent increases in prolifera-
tion, invasion, and metastasis [15, 66, 68–72]. E-cadherin
dysfunction may occur through several mechanisms, in-
cluding CDH1 mutations, epigenetic silencing by pro-
moter hypermethylation, loss of heterozygosity (LOH),
transcriptional silencing by a variety of transcriptional re-
pressors that target the CDH1 promoter, and microRNAs
that regulate E-cadherin expression [67]. However, only
the presence of E-cadherin structural alterations repre-
sents a poor prognostic factor [72]. E-cadherin somatic al-
terations exist in all clinical settings and histotypes of GC
and are associated with different survival rates [72]. These
alterations are, presently, non-targetable as this would
require restoring E-cadherin expression by gene ther-
apy [15]. Nevertheless, E-cadherin is a potential
predictive marker of response to therapy since its im-
pairment decreases tumour cell sensitivity to conven-
tional and targeted therapies [72, 73]. Screening for
CDH1 mutations at the time of GC diagnosis may
help to predict patient prognosis and is likely to im-
prove management of patients [71].
Multiple germline E-cadherin mutations have been re-
ported in hereditary diffuse gastric cancer (HDGC) [74].
Analysis of families demonstrated an association be-
tween GC development and germline mutations in the
E-cadherin (CDH1) gene. The CDH1 gene mutations
have been scattered across the 16 exons this gene en-
compasses, with approximately 75 % being truncating
and 25 % missense in nature [75, 76]. Moreover, there
have even been large deletions of the E-cadherin gene
identified in a small percentage (4 %) of HDGC families,
likely involving nonallelic homologous recombination in
Alu repeat regions [77]. Furthermore, 70 % of CDH1
mutation-negative HDGC probands display germline
monoallelic CDH1 RNA downregulation (allelic imbal-
ance), reinforcing the role of the CDH1 locus in this
disease [78]. HDGC tumours appear when complete
somatic CDH1 inactivation is acquired, leading to reduced
or absent E-cadherin expression [75, 79]. This occurs
through second-hit mechanisms, pursuing Knudson’s
model of tumour suppressor gene inactivation [80, 81].
CDH1 promoter hypermethylation is the most frequent
second-hit inactivation mechanism in HDGC primary tu-
mours, whereas a second mutation or deletion (LOH/in-
tragenic deletions) is less frequently identified [70, 82–84].
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The cumulative risk estimate for advanced GC by 80 years
of age was estimated to be 67 % for men and 83 % in
women with wide confidence intervals, as these were
based on 11 HDGC families [85].
A study of 42 families diagnosed with HDGC trait
by having at least two members affected had an E-
cadherin mutation identified in 40 % of cases. If the
clinical criteria were less stringent to include only
one GC occurring before 50 years of age, then more
than half the cases had E-cadherin mutations [86].
When large deletions were screened in addition to
point mutations and small frameshift mutations, 46 %
of 160 high-risk families were found to have a germ-
line E-cadherin gene alteration [77]. It is noteworthy
that more than half to up to two thirds of HDGC
families reported have proven negative for the E-
cadherin gene mutation [77, 87]. Allele expression
imbalance of CDH1 was noted in a subset of these
families [78]; however, most of these families likely
have other molecular alterations underlying their can-
cer predisposition that are yet to be discovered [88].
The frequency of abnormal E-cadherin expression
among sporadic DGC varies and has been reported as
7 [89], 38 [66], 46 [90], and 82 % [91]. CDH1 somatic
alterations were found in approximately 30 % of all
patients with GC [71]. No germline mutations of this
gene were detected in apparent sporadic diffuse GC
cases with a mean age of 62 years in Great Britain
[92]. Furthermore, a study of 25 sporadic diffuse GCs
identified 1 case with a germline E-cadherin mutation
and none in 14 intestinal-type GCs [93]. Molecular
variables such as CDH1 alterations may be crucial to
better define the survival of patients with a family
history.
Abnormal E-cadherin expression may be used as a
predictive factor for tumour invasiveness in gastric
adenocarcinoma. One study showed a significant correl-
ation between abnormal E-cadherin expression and
tumour grade and regional lymph node involvement
[66]. Another study showed that E-cadherin methylation
was correlated with size of tumour, tumour stage, and
nodal metastases [94]. However, one study found that E-
cadherin mutation was not correlated with tumour grade
or stage [95]. In keeping with most studies finding a cor-
relation of abnormal E-cadherin expression with adverse
clinicopathologic factors, tumours with CDH1 structural
alterations displayed a significantly poorer survival
rate than tumours negative for CDHI alterations or
tumours with epigenetic CDH1 alterations [71]. For
instance, one study found that patients with GC dis-
playing CDH1 exon 8/9 deletions (structural) have a
worse clinical evolution and a shorter OS [96]. Over-
all, abnormal E-cadherin expression favours a worse
prognosis for GC patients.
FGFR/EGFR/mTOR/MET
Important biomarkers in GC currently being investi-
gated include the FGFR, the hepatocyte growth factor
receptor (HGFR, MET), and mTOR [15].
FGFR family members (FGFR1, FGFR2, FGFR3, and
FGFR4) belong to the RTK superfamily [15]. In a recent
genomic survey of GC using high-resolution single-
nucleotide polymorphism (SNP) arrays, FGFR2 copy
number gain was found in 9 % of tumours and was more
common than EGFR (8 %), HER2 (7 %), or MET (4 %)
copy number gains [97]. FGFR2 has therefore attracted
significant attention as a potential candidate for targeted
therapy in GC [15]. The small-molecule FGFR2 inhibi-
tor, dovitinib (TKI258), has demonstrated growth inhibi-
tory activity in FGFR2-amplified GC cell lines and
xenografts. Ongoing phase II studies will be helpful to
clarify the role of dovitinib in patients with FGFR-
amplified metastatic GC [97].
Phosphatidylinositol-3-kinase (PI3K)/mTOR repre-
sents one common final convergence signalling path-
way originated by the activation of several RTKs.
Oncogenic mutations in PIK3CA (gene encoding the
alpha p110 catalytic subunit) of PI3K have been ob-
served in GC, constitutively activating the PI3KA/
mTOR pathway [15, 98]. Studies in GC have reported a
mutation frequency ranging from 5 to 67 % [99–102].
In particular, EBV-positive tumours have a strong pre-
dilection for PIK3CA mutations [100]. Misregulation has
been associated with increased lymph node metastases
and decreased survival of GC patients [15, 103, 104].
Everolimus is an mTOR inhibitor that has shown potential
benefit in advanced GC in early phase 2 trials [105, 106].
A phase 3 trial compared everolimus with placebo in 656
patients with chemotherapy refractory advanced GC
[107]. Only a trivial improvement in PFS was noted
(median 1.7 versus 1.4 months; p < 0.001). There was
no significant improvement in OS (median 5.4 versus
4.3 months; p = 0.124).
EGFR, another member of the human tyrosine kinase
receptor family, has been shown to be overexpressed by
IHC in 27 % of GCs, whereas gene amplification by
FISH was evident in less than 3 % in one large series
[108]. Another series using FISH found an incidence of
EGFR amplification to be ~5 % [109]. EGFR amplifica-
tion was found to be 8 % using SNP assays [97]. EGFR
overexpression has been associated with the presence of
moderately or poorly differentiated histology, higher
stage, and poor survival [108].
The addition of an anti-EGFR monoclonal antibody
with cytotoxic chemotherapy, however, has failed to
demonstrate improvement in the outcomes of patients
with advanced GC. Unlike HER2 target-directed therapy,
there are no established biomarkers to predict response
to EGFR inhibitors. The predictive value of EGFR
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mutation, increased EGFR copy number, and K-ras mu-
tation status in GC remains controversial. Two random-
ized clinical trials “EXPAND” and “REAL3” evaluated
efficacy of an anti-EGFR monoclonal antibody (panitu-
mumab or cetuximab) in combination with chemother-
apy in patients with advanced gastric and oesophageal
cancer [110, 111]. In the EXPAND trial, 904 patients
with advanced GC were randomized to capecitabine and
cisplatin plus cetuximab or chemotherapy alone. The
median PFS of patients who received chemotherapy plus
cetuximab was 4.4 months compared with 5.6 months
with chemotherapy alone [110]. In the REAL3 trial, 553
patients with advanced gastric and oesophageal cancer
were randomized to chemotherapy plus panitumumab
or chemotherapy alone. Median OS of patients who re-
ceived chemotherapy was 11.3 months compared with
8.8 months if they received chemotherapy plus panitu-
mumab (p = 0.013) [111]. In addition to anti-EGFR
monoclonal antibodies, orally active tyrosine kinase in-
hibitors (TKIs), small molecules that block the binding
site of the EGFR tyrosine kinase, have been evaluated in
patients with chemotherapy refractory advanced gastric
and oesophageal cancer. In a phase II trial of 70 patients,
erlotinib monotherapy resulted in a response rate of 9 %
in patients with gastroesophageal junction cancer but
none in the GC subgroup [112]. At the present time,
anti-EGFR therapies do not add to conventional chemo-
therapy. There is a need for further investigations to
identify subset of patients who will benefit from EGFR
blockade.
MET
MET (encoded by MET) belongs to the HGFR family
[15]. MET is a transmembrane tyrosine kinase receptor
with high affinity for hepatocyte growth factor/scatter
factor (HGF/SF). Auto-phosphorylation of MET acti-
vates several signalling transduction cascades, leading
to cancer cell proliferation, angiogenesis, invasion, and
metastases [113].
MET amplification and/or overexpression of its protein
product has long been implicated in the pathogenesis of
GC, with many reports based on gene copy number, RNA
expression, and/or protein expression, supporting its role
as a poor prognostic factor [114–117]. Nevertheless, the
prevalence of METamplification in GC varies widely in the
literature from 0 [118] to 68 % [113, 115]. This discrepancy
is greatly attributed to the methodology employed to detect
gene amplification/copy number gain and/or protein ex-
pression [15]. MET-positive tumours were more frequently
associated with serosal invasion and other unfavourable
features [118]. In all studies [97, 115–117], the GC patients
with polysomic and/or amplified MET showed poorer
disease-free survival and OS in comparison with the non-
polysomic MET [15]. Another study has reported a
significantly worse prognosis for MET-positive compared
with MET-negative tumours [119]. Although MET amplifi-
cation may play a central role in determining GC progno-
sis, future studies should focus on the possible negative
predictive role for response to chemotherapy or targeted
therapies [113].
Despite the fact that aberrant up-regulation of the
MET/HGF pathway is associated with poor prognosis in
GC, anti-MET therapies have shown limited efficacy in
advanced GC. Onartuzumab is a fully humanized, mono-
valent anti-MET antibody that inhibits HGF binding and
receptor activation. The efficacy of onartuzumab in com-
bination with chemotherapy (mFOLFOX6) in the first-line
setting was examined for metastatic, HER2-negative gas-
troesophageal cancer [120]. In the MET-positive sub-
group, median PFS was 5.95 months for onartuzumab and
6.8 months for placebo (HR 1.38 [0.60–3.20]). Likewise,
the interim results of a phase II study of foretinib, a MET
TKI, showed minimal activity in a MET-unselected patient
cohort [121]. Despite early negative results, several novel
MET inhibitors are now being evaluated in metastatic or
unresectable GC in an attempt to identify patients who re-
spond to MET inhibitors.
PD-L1 expression
Programmed death-1 (PD-1) is a key immune checkpoint
receptor critical for the regulation of T cell function dur-
ing immunity and tolerance. The PD-1 surface receptor
binds to two ligands, PD-L1 and PD-L2, which are
expressed on tumour cells. PD-1-PD-L interactions con-
trol the induction and maintenance of peripheral T cell
tolerance. Tumours use the PD-1 pathway to evade im-
mune surveillance and to prevent the immune system
from rejecting the tumour [122]. The frequency of pro-
grammed death ligand 1 (PD-L1) overexpression, a puta-
tive response biomarker, approaches 40 % in GC [123].
The EBV-positive sub-type of tumours has shown in-
creased expression of PD-L1/2 [14]. Pembrolizumab is an
anti-PD1 monoclonal antibody that has shown efficacy in
advanced PD-1-expressing GC. In an early phase trial, 65
patients who had distinctive stromal or ≥1 % tumour nest
cell PD-L1 staining were treated with pembrolizumab.
The objective response rate was 22 %, and median re-
sponse duration was 24 weeks. The 6-month PFS was
24 % and the 6-month OS was 69 % [124]. The results of
this study have prompted expansion of immune check-
point inhibitors in advanced GCs. Targeting the PD-1
pathway and immune checkpoint blockade appears to be
a promising novel approach for the treatment of GC.
TP53
The TP53 gene encodes a nuclear p53 protein of 393
amino acids, which acts as a potent transcription factor
with a key role in the maintenance of genetic stability
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[125, 126]. The function of TP53 gene is usually altered
through LOH, mutations, and rarely by DNA methyla-
tion [126]. TP53 mutation is one of the most prevalent
genetic alterations in GC and associated with the CIN
sub-type of GC [14, 126]. More than one mutation may
be present in a single tumour resulting in heterogeneity
of the TP53 mutational status [126].
There are conflicting results with respect to the preva-
lence of TP53 mutations and their relationship to histo-
logical type or tumour stage of GC. Some studies
showed that mutations tend to affect mainly intestinal-
type tumours, while others found that the incidence of
mutation is similar in both intestinal and diffuse-type tu-
mours, ranging between 16 and 65 % of the cases stud-
ied. The frequency of TP53 abnormalities in both early
and advanced intestinal type is consistent, similar to that
observed in advanced diffuse type, while in early diffuse-
type TP53 mutations are uncommon [126–130].
The expression of p53 in non-tumour gastric mucosa
with dysplasia was significantly higher than that in the
mucosa without dysplasia. Overexpression of p53 pro-
tein was associated with the size of tumours that may
help in diagnosis and prognostic prediction of GC [131].
However, the prognostic impact of p53 abnormalities on
this neoplasm remains controversial. A significant asso-
ciation between p53 overexpression and the metastatic
spread to lymph nodes or shortened survival has been
described by some studies on GC but not by others
[126]. At this time, p53 is not a reliable prognostic factor
for GC.
Microsatellite instability
Microsatellites are short iterations of 1–6 nucleotide
long units, non-randomly distributed in both prokaryotic
and eukaryotic genomes [12]. Mismatch repair (MMR)
deficiency leads to a tumour phenotype known as micro-
satellite instability (MSI), in which cells accumulate
genetic errors [15]. Several reports have shown the asso-
ciation of GC with MSI [132, 133]. MSI has been re-
ported in 15 to 30 % of GC, mainly due to epigenetic
silencing via hypermethylation of the MLH1 promoter
[134, 135]. MSI-positive GC generally develops later in
life and has a favourable prognosis when compared with
MSI-negative tumours [136, 137]. The methylation of
hMLH1 gene and its loss of expression increase with in-
creasing age of the GC patient [138]. Studies have shown
a strong association of MSI in GC with intestinal type,
which undergoes more genomic instability in compari-
son to the diffuse type [12]. Moreover, MSI GC is more
common in the distal part of the stomach [137, 139].
Interestingly, MSI tumours usually have an overall long-
term prognosis that is favourable even in patients
with advanced disease due to the fact that these tu-
mours have a lower ability to invade serosal layers
and are associated with a lower prevalence of lymph
node metastases [135, 137, 139–141]. There are also
higher survival rates in patients with advanced MSI
GC in comparison to patients with other types of GC
even with the same identical stage of the disease
[142]. Information is scarce as to the prognostic value
of EGFR, HER2, or VEGFA expression in the MSI
subset of GC [135]. The MSI status certainly appears
to be an independently positive prognostic factor, and
future studies will need to determine the impact of




MicroRNAs (miRNAs) are short fragments of noncoding
RNAs comprising 18 to 24 ribonucleotides that can
regulate the expression of genes by directly binding to
the 3′UTR region of their target gene mRNA and
impairing their translation [143, 144]. miRNAs have
been found to regulate a variety of cellular processes
such as cell proliferation, differentiation, invasion, mi-
gration, and epithelial-mesenchymal transition [143]. A
single miRNA can regulate the expressions of thousands
of genes and participate in the regulation of the whole
cell cycle [145]. In detail, miRNAs negatively regulate
the expression of cancer-related genes by decreasing the
expression of tumour suppressor genes or enhancing the
expression of oncogenes, or as modulators of cancer
stem cells and metastases [146]. Accumulating evidence
suggests that miRNAs play an important role in GC, but
the role of specific miRNAs involved in this disease re-
mains elusive [143].
Serum and plasma miRNAs are more stable and rela-
tively easier to access than tissue samples [147]. The sta-
bility of tumour-associated miRNA in blood allows it to
be a novel noninvasive tumour biomarker for cancer de-
tection [148]. Circulating miRNAs must demonstrate
several hallmark characteristics to be considered as reli-
able biomarkers: (i) stable and able to be quantified in
clinical samples; (ii) present at undetectable or low levels
in samples from individuals without cancer, while being
expressed by cancer cells at moderate or high levels; (iii)
exhibit biological functions mechanistically linked to
malignant tumour progression; and (iv) provide diagnos-
tic or prognostic information [149, 150].
The results on expression of miRNAs are inconsistent,
and it is hard to select a suitable miRNA as a cancer bio-
marker. Furthermore, there is no consensus regarding
whether plasma or serum is preferable for use as a sam-
ple, and there is a limitation to analysing the miRNA ex-
pression results of both plasma and serum [145].
Previous studies have shown that some miRNAs have
been inconsistently reported when being used as a
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cancer biomarker [151, 152]. Possible reasons for these
observed inconsistencies are the diverse experimental
techniques, lack of sufficient relevant clinical data, the
heterogeneous tissue samples, and poor study design
[145, 153].
Numerous miRNAs have been identified as dysregulated
in GC, either tissues or cell lines, many of which have also
been associated with clinicopathologic features and/or
survival. A number of reviews have specifically addressed
the role of miRNAs in GC with comprehensive tables
[154, 155]. However, to date there are no validated thera-
peutic trials showing miRNAs are an effective novel prog-
nostic, predictive, or therapeutic biomarker.
Long noncoding RNAs
Long noncoding RNAs (lncRNAs) are functional RNAs
longer than 200 nucleotides [156]. According to the
proximity to protein-coding genes, lncRNAs can be
classified as sense, antisense, divergent or bidirectional,
intronic, and intergenic [157]. As entities of transcrip-
tional control, generally it is understood that lncRNAs
may perform their functions in at least two ways: (i) as
scaffoldings in ribonucleoprotein complexes, e.g. tran-
scription or chromatin-modifying factors, acting in cis or
in trans on the genome [158], and (ii) as incidental by-
products of a negative type of transcriptional regulation
termed “transcriptional interference” [159]. Unlike
protein-coding genes, the function of these lncRNAs
and their relevance to disease remain unclear [156]. Re-
cently, a new regulatory mechanism has been identified
in which crosstalk between lncRNAs and mRNA occurs
by competing for shared miRNAs response elements. In
this case, lncRNAs may function as competing endogen-
ous RNAs to sponge miRNAs, thereby modulating the
de-repression of miRNA targets and imposing an add-
itional level of post-transcriptional regulation [160].
LncRNAs are still an emerging field. However, accu-
mulating evidence has demonstrated that many lncRNAs
are dysregulated in GC and closely related to tumorigen-
esis, metastases, and prognosis or diagnosis [156]. A
total of 135 lncRNAs have been found to be aberrantly
expressed in GC tissues [11, 161]. These may be poten-
tial prognostic biomarkers for GC and await future stud-
ies to further elucidate their relevance.
Matrix metalloproteinase
The matrix metalloproteinases (MMPs) are a family of
24 zinc-dependent endopeptidases in humans that de-
grade components of the extracellular membrane (ECM)
[162]. MMPs participate in several normal and patho-
logical processes, and their activity is mainly modulated
by the action of the tissue inhibitor of metalloproteinase
(TIMP) [163]. MMPs take part in breaking down the
extracellular matrix in normal physiological processes
[164]. Specifically, it has been reported that both the ex-
pression of some MMP proteins and mRNA may have a
large influence on GC [165, 166]. Studies regarding
regulation of MMPs and TIMPs in GC have suggested
that these molecules could be useful as markers of depth
of invasion, metastases, and peritoneal dissemination
[162]. There are some conflicting results, which are most
likely related to methodological aspects and to the het-
erogeneity of the patient populations [167].
MMPs have been identified as up-regulated in GC, either
tissues or cell lines, and have also been associated with
clinicopathologic features and/or survival including MMP
3 [168], 7 [168–170], 11 [162, 168], 9 [168, 171, 172], 12
[168], 21 [168, 173], MT1 [174–176], 14 [177], 1 [162], 2
[162], and 28 [162].
MMP inhibitors, however, have shown limited clinical
benefit. For example, a randomized, double-blind,
placebo-controlled study evaluated efficacy of orally ad-
ministered MMP, marimastat, in 369 patients with
chemotherapy refractory advanced gastric and gastro-
esophageal cancer. A modest difference in survival was
noted. The median survival was 138 days for placebo
and 160 days for marimastat, with a 2-year survival of 3
and 9 %, respectively. The treatment was complicated by
poor tolerability and was associated with musculoskel-
etal pain and inflammation [178]. Though many studies
have identified the possible role of MMPs in GC, the
clinical correlation is still lacking and many more studies
will need to be carried out.
Conclusions
GC is common according to global estimates of cancer
and is a frequent cause of cancer-related mortality with
a poor survival. At present, although the role of many
genetic alterations discovered in GC seems unclear, they
represent a promising tool for stratifying patients ac-
cording to tumour biological behaviour and likelihood of
response to systemic therapy [15]. Nevertheless, to date,
except for HER2, there are no established evidence-
based biomarkers predictive of tumour response to tar-
geted agents, and the majority of patients do not yet
benefit from molecularly directed therapies.
Most analyses in the literature consider a limited num-
ber of cases. As a result, despite the huge amount of
data, no novel/reliable molecular marker has been intro-
duced in the frame of secondary prevention strategies,
so far [179]. It is therefore important to undertake retro-
spective studies in which tumour samples from patients
that have undergone GC therapy are mined for single or
combinations of biomarkers that can predict favourable/
unfavourable response towards a certain chemothera-
peutic regimen or define the use of multiple therapy
regimens in GC. Independent validation of the most
promising prognostic and predictive biomarkers will
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then be required before they can be routinely employed
in clinical practice [15]. The search for a diagnostic bio-
marker is particularly critical for patient outcomes as
early diagnosis would be instrumental in increasing sur-
vival. Future studies with identification and validation of
diagnostic, prognostic, predictive, and therapeutic bio-
markers will aid in the understanding of GC resulting in
personalized pathway-driven targeted therapy with im-
proved patient outcomes [180].
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